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Abstract
Colorectal cancer (CRC) has long been known for its tight association with chronic inﬂammation, thought to play a key role
in tumor onset and malignant progression through the modulation of cancer stemness. However, the underlying molecular
and cellular mechanisms are still largely elusive. Here we show that the IL-6/STAT3 inﬂammatory signaling axis induces the
deacetylation of FRA1 at the Lys-116 residue located within its DNA-binding domain. The HDAC6 deacetylase underlies
this key modiﬁcation leading to the increase of FRA1 transcriptional activity, the subsequent transactivation of NANOG
expression, and the acquisition of stem-like cellular features. As validated in a large (n= 123) CRC cohort, IL-6 secretion
was invariably accompanied by increased FRA1 deacetylation at K116 and an overall increase in its protein levels,
coincident with malignant progression and poor prognosis. Of note, combined treatment with the conventional cytotoxic
drug 5-FU together with Tubastatin A, a HDAC6-speciﬁc inhibitor, resulted in a signiﬁcant in vivo synergistic inhibitory
effect on tumor growth through suppression of CRC stemness. Our results reveal a novel transcriptional and posttranslational
regulatory cross-talk between inﬂammation and stemness signaling pathways that underlie self-renewal and maintenance of
CRC stem cells and promote their malignant behavior. Combinatorial treatment aimed at the core regulatory mechanisms
downstream of IL-6 may offer a novel promising approach for CRC treatment.
Introduction
Tumor-promoting inﬂammation is emerging as one of the
main hallmarks of cancer [1] and colorectal cancer (CRC)
best exempliﬁes the tight link between inﬂammation, tumor
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onset, and malignant progression [2]. We and others have
previously shown that interleukin-6 (IL-6) represents a key
inﬂammatory cytokine and that its downstream effector
STAT3 (signal transducer and activator of transcription 3)
underlies CRC proliferation, epithelial-to-mesenchymal
transition (EMT) [3], tumorigenesis [4], and stemness [5].
In hepatocellular carcinoma (HCC), tumor-associated
macrophages promote CD44+ stem-like cell expansion,
and IL-6/STAT3 signaling inhibition using Tocilizumab
(TCZ) inhibits this expansion [5]. However, the down-
stream effectors of the IL-6/STAT3 signaling axis that
underlie cancer stem cell (CSC) properties are yet unknown.
Conventional cytotoxic cancer treatment is only partly
effective because it mainly targets the bulk of cancer cells
without affecting the stem-like cancer cells capable of tumor
initiation, self-renewal, differentiation, and chemoresis-
tance. The latter highlights the need to circumvent therapy
resistance by speciﬁcally targeting the stem-like cellular
component of malignancies. Thus far, CD44, CD133, and
CD166 were shown to represent informative CSC markers
in colon cancer [6–9]. Moreover, it has been demonstrated
that NANOG, a core homeobox transcription factor (TF)
playing key roles in the maintenance and preservation of
self-renewal in embryonic stem cells (ESCs), is also
expressed in CSCs from different tumor types, including
liver and colon cancers [10–13].
FRA1 is a member of the FOS family of TFs encoded by
the FOSL1 gene and an important transcriptional down-
stream target of the IL-6/STAT3 signaling axis leading to
CRC aggressiveness through EMT induction [3]. Accord-
ingly, FRA1 is highly expressed in multiple cancers and is
thought to play key roles in neoplastic transformation [14],
motility [15], cancer drug addiction [16], and stemness [17,
18]. Elevated FOSL1 (FRA1) expression level was reported
to result from the activation of the IL-6/STAT3 [3], RAS-
RAF-MEK-ERK-RSK [14, 15], and PKCα/θ [17, 19]
pathways both at the transcriptional and posttranslational
levels. In the latter case, phosphorylation of four C-terminal
residues, namely, Ser-252, Ser-265, Thr-223, and Thr-230,
inhibits FRA1 degradation [15, 19].
Acetylation is a well-known regulatory posttranslational
modiﬁcation. In particular, acetylation at speciﬁc residues of
several TFs has been shown to represent an important reg-
ulatory mechanism. Notably, lysine acetylation is not only
restricted to histones but is also found in numerous TFs,
including p53, nuclear factor (NF)-κB, and STAT3 [20].
Mechanistically, TF acetylation leads to changes in protein–
protein and protein–DNA interaction [21–23], thus resulting
in a plethora of downstream effects including increased/
decreased transcription, protein stabilization, steric preven-
tion of ubiquitination, and chromatin remodeling.
In the present study, we investigated posttranslational
regulatory mechanisms downstream of the IL-6/STAT3/
FRA1 inﬂammatory signaling axis that mediate colon cancer
stemness and malignancy and explored novel combinatorial
therapeutic approaches to target CRC stem and bulk cells.
Results
IL-6 promotes colon cancer stemness in an FRA1-
dependent manner
In colon cancer, IL-6 is known to be secreted by stromal
ﬁbroblasts, several types of immune cells, and by par-
enchymal cancer cells to activate STAT3 signaling, thereby
mediating tumor-promoting effects [4]. In view of this, we
ﬁrst excluded autocrine IL-6 secretion in the two CRC cell
lines employed in this study, namely, DLD1 and HT-29, by
enzyme-linked immunosorbent assay. As shown in Figure
S1a, almost no IL-6 was detected in either cell line, inde-
pendently of FOSL1 expression. Next, we determined the
effects exerted by recombinant IL-6 on both cell lines.
Phenotypic analyses by in vitro cell migration, invasion,
sphere formation, and chemo-resistance assays and by
in vivo lung metastasis assay in nude mice consistently
indicated that IL-6 exposure promoted CRC stemness and
malignancy (Figure S1b-S1e).
Previously, we reported that IL-6-activated STAT3
upregulates transcription of the FOSL1 gene by directly
binding to its promoter and further promoting CRC malig-
nant progression through EMT activation [3]. As shown by
western blot analysis in Fig. 1a, IL-6 stimulation resulted in
STAT3 pathway activation and up-regulation of FRA1,
SOX2, and NANOG expression in both DLD1 and HT-29
cell lines (Fig. 1a). Accordingly, inhibition of the IL-6/
STAT3/FRA1 inﬂammatory signaling axis by anti-human
IL-6R TCZ and by small interfering RNA (siRNA)
knockdown of STAT3 signiﬁcantly reduced sphere-
formation capacity and chemo-resistance of DLD1 cells
upon IL-6 stimulation (Figure S1f and S1g; Fig. 1b).
To determine the effects of IL-6 on cancer stem cells, we
measured by ﬂow cytometry the expression of two colorectal
CSCs markers, namely, CD44 and CD133 [6, 7]. Upon IL-6
treatment, the relative proportion of the
CD44+/CD133+ CSC subpopulation increased from 3.3% to
13.8% and from 4.4% to 15.7% in DLD1 and HT-29,
respectively (Figure S1h). Next, we sorted by ﬂuorescence-
activated cell sorter (FACS) the CD44+/CD133+ and CD44
−/CD133− subpopulations from IL-6-treated DLD1 cells.
Sphere-formation and subcutaneous transplantation assays
indicated that CD44+/CD133+ cells were characterized by
increased self-renewal in vitro and tumor-propagating capacity
in vivo when compared with CD44−/CD133− cells (Figure
S1i and S1j). Of note, IL-6 treatment enhanced these features
in both subpopulations.
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Fig. 1 Interleukin (IL)-6 promotes colon cancer stemness in an
FRA1-dependent manner. a Western blot analysis of DLD1 and
HT-29 cells cultured in the presence/absence of 50 ng/ml IL-6 for
24 h. Protein levels of STAT3-pY705, STAT3, FRA1, SOX2,
NANOG, and GAPDH were examined. b DLD1 cells were cultured
in medium supplemented with the chemotherapeutic drugs
5-Fluorouracil (5-FU) and cisplatin and in the presence/absence of
IL-6 (50 ng/ml), Tocilizumab (5 μg/ml), and siSTAT3. The per-
centage of apoptotic (Annexin V+) cells were employed as a
measure of sensitivity to the treatment when compared to the
controls. c CD44+/CD133+ and CD44−/CD133− DLD1 cells were
sorted by ﬂuorescence-activated cell sorter (FACS) and cultured in
the presence/absence of IL-6 for the indicated times. These cultures
were monitored at the indicated time points by FACS analysis.
Quantiﬁcation of CD44+/CD133+ cells in triplicate (mean ± SD)
are depicted. d CD44/CD133 FACS analysis of parental (FOSL1
+/+) and FOSL1−/− HT-29 cells cultured in the presence/absence of
IL-6 for 7 days. The relative percentage of the CD44+/CD133+
subpopulation is indicated in the histogram. e FRA1 transcriptional
activity was measured in shNC, shFOSL1#1, and shFOSL1#2
DLD1 cells cultured in the presence/absence of IL-6 (50 ng/ml).
f, g Migration and invasion assays (d) and sphere formation assays
(e) were performed with non-target control (shNC), shFOSL1#1,
and shFOSL1#2 DLD1 cells cultured in the presence/absence of
IL-6. Results are shown as histograms showing quantitative values
of the number of cells (or spheres) from triplicate experiments
(mean ± SD). h shNC and FOSL1 knockdown (shFOSL1#1 and
shFOSL1#2) DLD1 cells were cultured in medium supplemented
with the chemotherapeutic drugs 5-FU and Cisplatin and in the
presence/absence of IL-6 (50 ng/ml). The percentage of apoptotic
(Annexin V+) cells indicated that both shFOSL1#1 and
shFOSL1#2 were characterized by increased sensitivity when
compared to the shNC control cells. i 5 × 105 shFOSL1#2 and, as a
control, shNC DLD1 cells were cultured in the presence/absence of
IL-6 for 5 days and then injected subcutaneously into the
ﬂanks of BALB/C nude mice. DLD1 cells treated with IL-6
increased tumor mass when compared with the shNC group.
And this effect was attenuated upon FOSL1 knockdown. *p < 0.05,
**p < 0.01, ***p < 0.001. Unpaired t test. Data are presented as
mean ± SD
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Next, we cultured the sorted cells in the presence/absence
of IL-6 and followed their behavior by FACS analysis for
82 days. As depicted in Fig. 1c and Figure S1k, CD44
+/CD133+ DLD1 cells were maintained at a signiﬁcantly
higher percentage under constant IL-6 stimulation, thus
conﬁrming its positive effect on the maintenance of the
CSC subpopulation.
To assess whether IL-6 affects CSC properties through
FRA1, we stably overexpressed the FOSL1 gene in the
DLD1 and HT-29 cell lines (Figure S2a). Increased FOSL1
expression enhanced cell features including cell migration
and invasion (Figure S2b) and sphere formation (Figure
S2c). Accordingly, subcutaneous transplantation of FOSL1-
overexpressing DLD1 cells into nude mice revealed
increased tumorigenicity when compared with the empty
vector (EV) group, and IL-6 stimulation enhanced this
effect in EV group (Figure S2d).
To further study the role played by FOSL1/FRA1 in IL-
6-driven colon cancer stemness, FOSL1 gene knockout HT-
29 cells were constructed by TALEN technology. In FOSL1
−/− HT-29 cells, the IL-6-induced expansion of the CD44
+/CD133+ subpopulation was completely abolished, thus
reinforcing the relevance of the IL-6/FRA1 signaling axis in
regulating CSCs (Fig. 1d). Moreover, we knocked down
FOSL1 (shFOSL1#1 and shFOSL1#2) in DLD1 and HT-29
cells using a lentivirus-based approach (Figure S2e). FOSL1
knockdown caused a signiﬁcant impairment of FRA1
transcriptional activity as measured by the FRA1-Luc
reporter activity in the presence/absence of IL-6 in the
culture medium (Fig. 1e). Moreover, the positive in vitro
effects of IL-6 on migration, invasion, and sphere formation
were dramatically reduced by FRA1 downregulation (Fig.
1f, g; Figure S2f and S2g). In addition, FOSL1 knockdown
suppressed the IL-6-induced increase in chemo-resistance to
5-Fluorouracil (5-FU) and Cisplatin in DLD1 and HT-29
cells (Fig. 1h; Figure S2h). Consistent with the above
in vitro ﬁndings, FOSL1 knockdown also attenuated the
tumor-enhancing effect of IL-6 in nude mice (Fig. 1i).
Overall, these results indicated that activation of the IL-
6/STAT3/FRA1 inﬂammatory signaling axis promotes
CRC stemness and progression toward malignancy.
IL-6/STAT3-driven FRA1 Lys-116 deacetylation
increases its transcriptional activity
Acetylation of non-histone proteins represents a key tran-
scriptional regulatory event [20–23]. In order to elucidate
the mechanisms of FRA1 acetylation and its functional
consequences, a pan acetyl-lysine antibody (Ace-Lys) was
employed. Immunoprecipitation (IP) analysis of ectopically
expressed full-length and truncated (Flag- and Myc-tagged)
FRA1 in 293T cells showed that the CREB-binding protein
(CBP) can acetylate FRA1 and that the acetylated sites were
located in the NH2-terminal 130 residues of FRA1 (Figure
S3a and S3b). According to an online prediction tool [24],
the K116 and K121 residues represent potential FRA1
acetylation sites within the NH2-terminal fragment. Mass
spectrometric analysis of DLD1 cells conﬁrmed that both
Lys residues were indeed acetylated by CBP (Figure S3c).
Of note, these residues were localized within the FRA1
DNA-binding domain (DBD), highly homologous to the
corresponding domain in c-FOS. We then generated a
structure model of the analogous c-Jun/FRA1 complex
bound to the promoter motif showing that the K116 residue
was in direct contact with DNA (Fig. 2a). However,
alignment of the FRA1 and c-FOS sequences around the
K116Ac target region revealed the presence of a key dif-
ference, namely the L117 residue in FRA1 corresponding to
M149 in c-FOS (Figure S3d). In agreement with these in
silico predictions, IP analysis of ectopically expressed Flag-
EV, Flag-c-Fos and Flag-FRA1 in DLD1 cells showed that
K116Ac antibody could hardly recognize c-Fos compared
with FRA1 (Figure S3e). As shown in Figure S3f, the DBD
of FRA1 and FRA1-K116R reached stability during the last
50 ns of molecular dynamics (MD) simulations, while the
DBD of FRA1-K116Q ﬂuctuated during the entire MD
simulation, indicating that the DBDs of FRA1 and FRA1-
K116R are more stable than that of FRA1-K116Q upon
interaction with the target DNA domain. The protein–DNA
binding free energies for the three complexes were esti-
mated by MM/GBSA, and the binding afﬁnities for COM,
COM-K116Q, and COM-K116R were −189.97, −187.81,
and −194.23 kcal mol−1, respectively (Table S1), indicating
that the mutation of K116 to Gln weakened the binding of
FRA1 to DNA, while the mutation of K116 to Arg
strengthened the binding. To clarify the effect of the
mutations on the protein–DNA binding quantitatively, the
MM/GBSA free energy decomposition was performed. The
energy contributions of the residues at position 116 for the
DNA binding in the three systems were quite different
(K116= –5.41 kcal mol−1, Q116= –4.7 kcal mol−1, and
R116= –6.87 kcal mol−1). As for the residue116, the dif-
ference was mainly contributed from the polar energy terms
(ΔEele+ ΔGGB= –1.67, –0.61, and –2.73 kcal mol−1 for
K116, Q116, and R116, respectively) (Figure S3g).
Mutagenesis and luciferase reporter assays provided
experimental conﬁrmation of the above results: the FRA1-
K116R mutant that mimics deacetylation at the Lys-116
residue was characterized by an increment of FRA1 reporter
luciferase activity, whereas the acetylation mimic FRA1-
K116Q/E/A mutants resulted in a reduction of FRA1-luc
activity. Notably, the FRA1-K116R/K121R double mutant
had similar effects when compared with the single FRA1-
K116R mutant, while the K121R mutation alone did not
affect FRA1 reporter activity. Besides, both the Δ3 deletion
mutant (deletion of 3 C-terminal residues) and the
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dimerization-defective (L154A/L161A) mutant of FRA1
[25] did not affect FRA1-luc activity (Fig. 2b). Further-
more, additional experimental evidence excluded that the
K116 and K121 residues of FRA1 were involved in protein
stability and in its interaction with c-Jun (Figure S4a and
S4b).
To enable the analysis of K116 deacetylation in endo-
genous FRA1, we generated a polyclonal antibody speciﬁ-
cally recognizing the acetylated Lys-116 residue. The
speciﬁcity of the anti-K116Ac antibody was validated by
western blot and IP analyses (Figure S4c and S4d). Addi-
tional western blot analysis with the K116Ac antibody
showed an increase of approximately 2–3-fold in K116
acetylation by trichostatin A (TSA; an inhibitor of histone
deacetylase HDAC family I, II, and IV) but not by nicoti-
namide (NAM; an inhibitor of the SIRT family deacety-
lase), in both 293T and DLD1 cells (Fig. 2c). TSA
treatment did reduce FRA1 luciferase activity (Fig. 2d).
Hence, these results indicate that K116 deacetylation plays
a key role in the regulation of FRA1 transcriptional activity.
Since IL-6/STAT3 signaling positively affects FOSL1
transcription and thereby increases CRC stemness as shown
above, we asked whether FRA1 K116 deacetylation could
be directly involved in the modulation of CSCs properties.
As shown in Fig. 2e, FRA1 mainly localizes to the nucleus
of CRC cells in agreement with its function as a TF. After a
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short (0–3 h) exposure to IL-6, K116 acetylation level
readily decreased while the overall expression level of
FRA1 remained unchanged. Prolonged IL-6 treatment (6–
24 h) further increased FOSL1 transcription, though with a
decrease in the relative level of K116-acetylated FRA1
versus total FRA1 in both nucleus and cytoplasm (Fig. 2e).
Accordingly, siRNA-mediated STAT3 knockdown mark-
edly attenuated the IL-6-induced FOSL1 expression and
K116 deacetylation (Fig. 2f). Moreover, in vitro and in vivo
assays showed that cells expressing wild-type FRA1 or the
deacetylation mimic K116R were characterized by a sig-
niﬁcant increase in sphere formation and tumorigenic
potential when compared with the K116Q acetylation
mimic construct (Fig. 2g, h).
Taken together, these data showed that activation of the
IL-6/STAT3 signaling axis increases FRA1 level not only
by its transcriptional upregulation but also by
posttranslational deacetylation at its K116 site, thus pro-
moting colorectal CSC properties.
HDAC6 deacetylates FRA1 and underlies its
transcriptional activation downstream of IL-6/STAT3
Treatment with the HDAC inhibitor TSA, though not with
the SIRT inhibitor NAM, increased K116 acetylation (Fig.
2c), thus indicating that HDACs may underlie FRA1 dea-
cetylation. To provide experimental evidence for this, we
ﬁrst analyzed endogenous HDAC1–6 levels in the colon
cancer cell lines DLD1, HT29, and 293T and showed that
all six deacetylases are expressed albeit at different levels
(Figure S5a). Next, we expressed HDAC1–6 individually in
DLD1 cells. As shown in Fig. 3a, only HDAC6, an HDAC
family II deacetylase that mainly targets non-histone pro-
teins, decreased the K116 acetylation level of endogenous
FRA1 in CRC cells. Moreover, treatment with Romidepsin
(FK228; HDAC1/2 inhibitor) or Entinostat (MS-275;
HDAC1/3 inhibitor) had no evident impact on K116 acet-
ylation (Figure S5b). Accordingly, treatment with the spe-
ciﬁc HDAC6 inhibitor Tubastatin A increased K116
acetylation and decreased FOSL1 luciferase activity (Fig.
3b). Similar results were obtained by the HDAC6 knock-
down in DLD1 cells (Fig. 3c). In agreement with these
results, western blot analysis revealed that HDAC6 is
localized in both the nucleus and cytoplasm of CRC cells
(Figure S5c).
We then examined the physical interaction between
HDAC6 and FRA1 by co-IP analysis. Both ectopic and
endogenous HDAC6 could be coprecipitated by FRA1 in
293T and DLD1 cells (Fig. 3d, e). Moreover, this interac-
tion was enhanced by IL-6 and attenuated by siSTAT3 (Fig.
3e), thus indicating that IL-6/STAT3 signaling may posi-
tively affect the interaction of HDAC6 with FRA1 and
facilitate its deacetylation. Last, siRNA-mediated STAT3
knockdown markedly attenuated IL-6-induced K116 dea-
cetylation but had no effect on global HDAC6 expression
(Fig. 3f).
Overall, these results indicated that HDAC6 underlies
K116 deacetylation of FRA1 and its transcriptional activa-
tion downstream of IL-6/STAT3.
FRA1 trans-activates NANOG expression upon K116
deacetylation
To further explore direct transcriptional targets of FRA1 in
the regulation of colon cancer stemness, we analyzed
NANOG protein expression in FOSL1-overexpressing
DLD1 and HT-29 cells by western blot (Fig. 4a; Figure
S6a). FOSL1 expression resulted in an increment of
NANOG in both cell lines. Moreover, overexpression of
FOSL1 enhanced the transcriptional activities of the
Fig. 2 Interleukin (IL)-6/signal transducer and activator of transcrip-
tion 3 (STAT3)-driven FRA1 Lys-116 deacetylation increases its
transcriptional activity. a Left panel: schematic diagram of the
homology between structural domains in c-Fos and FRA1. The highest
homology is found in the DNA-binding domain that encompasses the
two FRA1 acetylated lysine residues (K116 and K121) identiﬁed by
mass spectrometry. Two leucine residues (L154 and L161) located in
the Leucine zipper domain (LZ) were responsible for FRA1 hetero-
dimerizing with the JUN family. Phosphorylation of many serine (S)
or threonine (T) residues of FRA1 in destabilizer domain (DEST)
increase its stability. Right panel: Charge density map of AP-1(c-Jun
and FRA1), DNA and the complex. Lys116 in FRA1 chain is shown
as sticks and spheres. b Relative luciferase activity in DLD1 cells co-
transfected with wild-type and (deletion and point) mutant FOSL1
constructs, together with pRL-TK as an internal control reporter. Δ3
deletion and L154A/L161A mutant constructs were here employed as
controls (*p < 0.05, **p < 0.01, ***p < 0.001, compared with the Flag-
EV; ##p < 0.01, ###p < 0.001, compared with the Flag-FOSL1). c
Immunoprecipitation (IP) analysis of FRA1 K116 acetylation. The
Flag-FOSL1 construct was transfected into 293T and DLD1 cells,
followed by treatment with the deacetylase inhibitors trichostatin A
(TSA) or nicotinamide, and IP with antibodies directed against Flag.
FRA1 acetylation was analyzed by western blot with the K116Ac-
speciﬁc antibody. d FRA1 transcriptional activity in response to TSA
treatment for 16 h and then measured by FRA1-Luc luciferase assay in
DLD1 cells. e DLD1 cells were cultured in the presence of IL-6 for the
indicated times and the cytoplasmic and nuclear protein fractions were
separated for western blot analysis with the indicated antibodies. K116
acetylation was detected with the K116Ac antibody and normalized
against the FRA1 protein. (LaminB1 and α-tubulin were employed as
nuclear and cytoplasmic protein control, respectively). f DLD1 cells
were transfected with siNC or STAT3 small interfering RNAs and
incubated with IL-6 for the indicated times. Cytoplasmic and nuclear
protein fractions were separated for western blot analysis using the
indicated antibodies. K116 acetylation was detected with K116Ac
antibody and normalized against the FRA1 protein. g, h HT-29
FOSL1−/− cells were constructed by TALEN and transfected with
expression constructs encompassing wild-type and mutated FOSL1.
These cells were then analyzed for their capacity to form spheres
in vitro (g) and to form subcutaneous tumors in vivo upon IL-6 sti-
mulation (h). *p < 0.05, **p < 0.01, ***p < 0.001. Unpaired t test.
Data are presented as mean ± SD
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Fig. 3 HDAC6 deacetylates FRA1 and underlies its transcriptional
activation downstream of interleukin (IL)-6/signal transducer and
activator of transcription 3 (STAT3). a Overexpression of HDAC6, but
not of other HDACs, decreases FRA1 acetylation levels. Each of the
Myc-tagged HDAC (1–6) were transfected into DLD1 cells and the
K116 FRA1 acetylation levels were determined by western blotting
with the K116Ac antibody and normalized against the FRA1 protein. b
Western blot analysis and relative FRA1-luc reporter activities in
DLD1 cells treated with the HDAC6 small inhibitor Tubastatin A for
the indicated times. c Small interfering RNA (siRNA) oligonucleotides
directed against HDAC6 were employed to transfect DLD1 cells. The
levels of endogenous K116 acetylation, FRA1, and HDAC6
expression were analyzed by western blot. And the FRA1-luc reporter
activity was assayed. d IP-Flag analysis of the interaction between
FRA1 and HDAC6 in 293T and DLD1 cells transfected with the
indicated plasmids. e DLD1 cells were transfected with Flag-FOSL1
and the indicated siRNAs, followed by IL-6 stimulation for 3 h. IP-
Flag analysis of HDAC6 was performed to assess the role of the IL-6/
STAT3 signaling pathway on the FRA1–HDAC6 interaction. f
DLD1 cells were transfected with non-target control oligonucleotides
(siNC) or STAT3 siRNAs and incubated with IL-6 for the indicated
times. The levels of STAT3-pY705, STAT3, HDAC6, α-tubulin, and
endogenous K116 acetylation protein were determined by western
blot. ***p < 0.001. Unpaired t test. Data are presented as mean ± SD
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NANOG-luc and SOX2-luc reporters in DLD1 cells but not
of LGR5-luc (Fig. 4b). Quantitative reverse transcriptase–
polymerase chain reaction (PCR) analysis conﬁrmed the
upregulation of endogenous NANOG gene expression,
though not of SOX2 and LGR5, in FOSL1-overexpressing
DLD1 cells (Fig. 4c).
Fig. 4 FRA1 trans-activates NANOG expression upon K116 deacety-
lation. a FRA1 and NANOG expression analysis by western blot in
empty vector (EV) and FOSL1-overexpressing DLD1 cells. b, c
Relative reporter luciferase activity (b) and mRNA levels (c) of
NANOG, SOX2, and LGR5 in EV and FOSL1-overexpressing
DLD1 cells. d Chromatin immunoprecipitation (ChIP) analysis of
DLD1 cells transfected with Flag-tagged wild-type and mutated
FOSL1 expression vectors. ChIP was performed with the Flag anti-
body. Quantitative reverse transcriptase–polymerase chain reaction
analysis was performed on immune-precipitated DNAs using a primer
pair speciﬁc for the NANOG promoter. e Relative luciferase activity of
wild-type and FBE-mutant (predicted FRA1-binding site) NANOG-luc
reporters in DLD1 cells transfected with wild-type and mutant FOSL1
expression constructs. f DNA pull-down assay analysis of FRA1-
binding ability to the biotin-labeled wild-type and FBE-mutant
NANOG promoter probe (−404/−1) in DLD1 cells stably over-
expressing wild-type and mutant FOSL1. Ku80 served as a control. g
Relative luciferase activity of the NANOG-Luc reporter in DLD1 cells
upon Tubastatin A treatment for 8 h. *p < 0.05, **p < 0.01, ***p <
0.001. Unpaired t test. Data are presented as mean ± SD
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Clinical validation of these results was provided by the
positive correlation between FOSL1 (encoding for FRA1)
and NANOG mRNA level in one CRC patient cohort from
the GSE24551-GPL5175 [26] dataset (Figure S6b).
To evaluate whether NANOG is directly regulated by
FRA1, we ﬁrst analyzed in silico its promoter sequence
using the JASPAR database (http://jaspar.genereg.net/) and
predicted a FRA1/AP-1-binding site (FBE) 45–56 nucleo-
tides upstream of the translational start site. Chromatin IP–
quantitativePCR analysis conﬁrmed that in DLD1 cells both
wild-type FRA1 and FRA1-K116R, though not FRA1-
K116Q, bind to the NANOG gene promoter through the
FBE site (Fig. 4d). Similar results were obtained by
NANOG gene luciferase reporter assays and by NANOG
gene promoter DNA pull-down assays, respectively (Fig.
4e, f). Moreover, treatment with the HDAC6 inhibitor
Tubastatin A signiﬁcantly decreased NANOG-luc activity
(Fig. 4g).
These results indicate that FRA1 upregulates NANOG
gene transcription by directly interacting with its promoter.
FRA1 deacetylation at K116 promotes its binding to the
NANOG promoter.
NANOG is a key downstream effector of IL-6/STAT3/
FRA1-driven CSC properties
In view of the IL-6/STAT3-driven enhanced expression of
both FOSL1 and NANOG (Figs. 1a and 5a), and of the
effects of FRA1 on NANOG transcriptional activity, we
further investigated the role played by key TF as the
downstream effector of the IL-6/STAT3/FRA1 signaling
axis in CSC properties. We showed that siRNA-mediated
STAT3 knockdown markedly attenuated IL-6-induced
FRA1 and NANOG expression levels in DLD1 cells (Fig.
5a). Notably, FOSL1 gene knockout signiﬁcantly blocked
IL-6-induced NANOG expression without affecting STAT3
activation in HT-29 cells (Fig. 5b). Thus NANOG is a
downstream effector of FRA1 in response to IL-6/
STAT3 stimulation.
Next, we overexpressed NANOG in DLD1 cells with
reduced FOSL1 expression (FOSL1 knockdown) (Figure
S6c). On its own, FOSL1 knockdown greatly reduced
chemoresistance to 5-FU and Cisplatin in DLD1 cells, and
this inhibitory effect was accordingly rescued upon NANOG
overexpression (Fig. 5c). Similar results pointing to an
increment of CSCs upon NANOG expression were obtained
by sphere-formation and mouse xenograft assays (Fig. 5d,
e).
We then knocked down NANOG in DLD1 and HT-29
cells using a lentivirus-based shRNA approach (Figure
S6d). The positive effects of IL-6 on migration, invasion,
sphere-formation ability, and chemoresistance were
signiﬁcantly reduced by NANOG knockdown (Fig. 5f–h;
Figure S6e-S6g). Consistent with the in vitro ﬁndings,
NANOG knockdown abolished the tumor-enhancing effect
of IL-6 (Fig. 5i). These data pointed at NANOG as an
important downstream effector of the IL-6/STAT3/
FRA1 signaling axis in the modulation of CSC properties.
Increased FRA1 protein expression with low K116
acetylation correlate with IL-6 and NANOG levels
and with poor prognosis among CRC patients
To validate the correlation between malignant behavior of
CRC and the expression levels of IL-6, K116Ac-FRA1,
FRA1, and NANOG, a cohort of prospectively collected
CRCs (n= 123) was employed. Immunoﬂuorescence ana-
lysis showed increased expression and nuclear co-
localization of FRA1, phosphorylated STAT3, and
NANOG protein in the cancer samples when compared with
adjacent (para-carcinoma) normal tissues (Fig. 6a; Figure
S6h). Immunohistochemical (IHC) analysis with the anti-
K116Ac antibody (whose speciﬁcity was previously vali-
dated; Figure S7a) showed that FRA1 was mostly identiﬁed
in the nucleus of cancer cells while its K116-acetylated
form mainly localized to the cytoplasm (Fig. 6b; Figure
S7b), thus indicating that phosphorylated STAT3 can acti-
vate FRA1 both by transcriptional upregulation and dea-
cetylation leading to increased NANOG expression levels.
Using consecutive tissue sections, IHC analysis further
conﬁrmed the positive correlation between the expression
level of FRA1 and IL-6 secretion (Fig. 6c). Notably, cancer
cells located in marginal areas adjacent to inﬂammatory
regions displayed stronger FRA1 immunoreactivity as well
as weaker K116Ac immunoreactivity when compared with
those in the center of the cancer mass. The latter observa-
tions suggest a paracrine effect of inﬂammatory cells on
FRA1 protein expression and K116 deacetylation on CRC
cells. HDAC6 localizes to both the cytoplasm and the
nucleus of cancer cells (Fig. 6c). Moreover, quantitative
analysis of the IHC results indicated that HDAC6 levels
inversely correlated with FRA1 acetylation at K116 in the
CRC cohort (Fig. 6d). IL-6 and FRA1 protein expression
was increased in tumor compared with non-tumor tissues
and positively correlated in the CRC cohort (Figure S7c-
S7e). These results were further validated with the
GSE24551-GPL5175 dataset (Fig. 6e; Figure S7f and S7g).
Last, we evaluated the prognostic value of increased
FRA1 combined with its decreased K116 acetylation in the
prospective CRC cohort. CRC patients with high FRA1 and
relatively low K116Ac expression are characterized by a
signiﬁcantly reduced overall survival when compared with
those with carcinomas characterized by low FRA1 and
relatively high K116Ac expression (Fig. 6f, g).
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Combined treatment of 5-FU with the HDAC6
inhibitor Tubastatin A synergistically inhibits CRC
stem-like properties and malignant growth
Based on the results thus far, inhibition of the enzymatic
machinery leading to FRA1-K116 deacetylation is expected
to result in improved clinical outcomes especially in
patients with increased IL-6 and FRA1 protein expression.
To provide proof of principle for this concept, we ﬁrst
sorted and cultured CD44−/CD133− and CD44+/CD133+
DLD1 cells in the presence/absence of IL-6 for 18 days to
then harvest them and separate the cytoplasmic and nuclear
protein fractions for western blot analysis. CD44+/CD133+
CSCs are characterized by lower K116 acetylation levels
both in the nucleus and cytoplasm compared with their
double-negative (CD44−/CD133−) counterparts (Fig. 7a).
Upon IL-6 stimulation, FRA1-K116 deacetylation was
observed in CD44+/CD133+ but not in CD44−/CD133−
cells. Likewise, we detected decreased K116Ac levels in
CD44+/CD133+ compared with CD44−/CD133−
DLD1 cells (Fig. 7b). These results indicate that colorectal
CSCs are relatively low in acetylated FRA1-K116 and that
IL-6 can further lower the relative level of the modiﬁed
protein in these stem-like cancer cells.
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To investigate whether the combination of 5-FU
and Tubastatin A is effective in targeting colon cancer
stem cells and tumor growth, in vitro drug resistance and
in vivo mouse xenograft assays were performed using sor-
ted CD44+/CD133+ and CD44−/CD133− DLD1 cells. We
showed that, while CD44+/CD133+ cells were more resis-
tant to 5-FU or Tubastatin A employed as single agents
when compared with CD44−/CD133− (Fig. 7c; Figure S8a),
the combination of 5-FU with the HDAC6 inhibitor
reversed their drug resistance phenotype (Fig. 7d; Figure
S8b). Western blot analysis of the cells treated with the
single and combined agents as in Fig. 7d showed that
Tubastatin A alone or combined with 5-FU treatment
resulted in increased expression of K116Ac and decreased
expression of NANOG (Figure S8c). The 5-FU/Tubastatin
A combination also had synergistic inhibitory effects on
DLD1 cell proliferation (Figure S8d). Accordingly, the
combined 5-FU/Tubastatin A treatment dramatically inhib-
ited xenograft growth in vivo (Fig. 7e). Of note, the toxicity
of the combined treatment was not higher than that of the
single agents, as shown by the unchanged body weight
among the different treated animals (Figure S8e). The
results are also supported by the observed positive corre-
lation between HDAC6 and NANOG expression in the
GSE24551-GPL5175 dataset (Figure S8f).
Overall, these results indicate that the combined treat-
ment of the chemotherapeutic agent 5-FU with the HDAC6
inhibitor Tubastatin A may prove to be a potential novel
curative approach for CRC patients, especially in those
cases where the IL-6/STAT3/FRA1 signaling axis is
activated.
Discussion
In this study, we show that FRA1 is a key downstream
effector of the IL-6–STAT3 signaling axis and that it
accounts for increased colon cancer stemness and malignant
behavior in the context of inﬂammation. We ﬁnd that, upon
IL-6/STAT3 signaling, HDAC6-driven deacetylation of a
previously unrecognized K116 residue in FRA1 activates its
transcriptional activity. Among the direct transcriptional
targets of FRA1, NANOG plays a central role in modulating
CRC stemness. Accordingly, increased FRA1 expression
combined with low levels of K116 nuclear acetylation
correlate with IL-6 secretion and with poor prognosis and
overall survival among CRC patients. Notably, the combi-
nation of 5-FU with the HDAC6 inhibitor Tubastatin A may
offer a potential novel therapeutic approach for colorectal
CSCs.
Increasing evidence has shown that, upon inﬂammation,
IL-6 activates STAT3 and exerts its predominant function in
the regulation and maintenance of liver and colon CSCs [5,
27] However, the underlying molecular mechanisms and the
IL-6/STAT3 downstream target genes that account for
increased cancer stemness and malignancy are to date yet
largely obscure. Previously, we reported that aberrant acti-
vation of STAT3, but not AKT or extracellular signal–
regulated kinase (ERK), mediated the IL-6-induced upre-
gulation of FRA1, required for EMT activation and
increased CRC aggressiveness [3]. Here we employed
human recombinant IL-6 to activate the IL-6/STAT3 path-
way and found that it promotes colon cancer stemness in an
FRA1-dependent manner. Consistent with our ﬁndings, the
role of FRA1 in regulating CSC properties has also been
reported in breast and liver cancer [17, 18]. In addition to
IL-6, another inﬂammatory cytokine, IL-22, was also
reported to promote pancreatic and CRC stemness via
STAT3 activation [28, 29], which suggested that these two
cytokines might coordinate with each other to modulate
colorectal CSC properties.
The activation of FRA1 downstream of IL-6/STAT3 is
known to mainly occur at the transcriptional level through
pSTAT3-dependent upregulation of the FOSL1 gene.
However, more recent studies have revealed that protein
modiﬁcations, e.g., phosphorylation of S265, T223, and
T230 [17, 19], are critical for FRA1 stabilization and for the
modulation of its downstream target genes. Also, FRA1
Fig. 5 NANOG is a key downstream effector of interleukin (IL)-6/
signal transducer and activator of transcription 3 (STAT3)/FRA1-dri-
ven CSC properties. a DLD1 cells were transfected with non-target
control (siNC) or STAT3 small interfering RNAs (siRNAs) and incu-
bated with IL-6 for the indicated times. The protein levels of STAT3-
pY705, STAT3, FRA1, NANOG, and GAPDH was examined by
western blot analysis with the respective speciﬁc antibodies. b Parental
(FOSL1+/+) and FOSL1−/− HT-29 cells were cultured in the presence/
absence of IL-6 for 24 h. The protein levels of STAT3-pY705, STAT3,
FRA1, NANOG, and GAPDH was examined by western blot analysis
with the respective speciﬁc antibodies. c–e Chemo-resistance (c),
sphere (d), and xenograft (e) formation assays of DLD1 cells featuring
different combinations of FOSL1 knockdown, NANOG over-
expression, and IL-6 stimulation (shNC= control for the siRNA-
driven FOSL1 knockdown). f, g Migration and invasion (f) and sphere
formation (g) assays were performed with shScramble (control for the
shRNA-driven NANOG knockdown) and shNANOG DLD1 cells cul-
tured in the presence/absence of IL-6. Results are shown as histograms
showing quantitative values of the number of cells (or spheres) from
triplicate experiments (mean ± SD). h shScramble and shNANOG
DLD1 cells were cultured in medium supplemented with the che-
motherapeutic drugs 5-Fluorouracil and Cisplatin and in the presence/
absence of IL-6 (50 ng/ml). The percentage of apoptotic (Annexin V+)
cells indicate that shNANOG DLD1 cells were characterized by
increased sensitivity when compared to the shScramble cells. IL-6
enhances chemo-resistance in shNC DLD1 cells, an effect that is
abrogated by the NANOG knockdown. i 5 × 105 shScramble and
shNANOG DLD1 cells were cultured in the presence/absence of IL-6
for 5 days and then injected subcutaneously into the ﬂanks of BALB/C
nude mice. In the shScramble group, DLD1 cells treated with IL-6
formed larger tumors, an effect that was abolished upon NANOG
knockdown. *p < 0.05, **p < 0.01, ***p < 0.001. Unpaired t test. Data
are presented as mean ± SD
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hetero-dimerizes with members of the JUN family, yet
another level of downstream gene expression regulation
[25, 30, 31].
Acetylation is known to regulate the functional activity
of TFs associated with the acquisition of CSC properties
[32, 33]. We show here that FRA1 is acetylated at a lysine
residue, K116, located within its DBD. Unlike its C-
terminal phosphorylation, K116 acetylation of FRA1
enhances its interaction with target DNA promoter
sequences without affecting its stability and interaction with
c-Jun. Ectopic expression of a de-acetylated (K116R) FRA1
allele results in a signiﬁcant increase in self-renew and
tumorigenic abilities. Although c-FOS is highly homo-
logous to the DBD domain in FRA1, c-Fos acetylation at
K148 (corresponding to K116 in FRA1) has not been
reported. Moreover, knockdown of c-Fos had no evident
Fig. 6 Increased FRA1 protein expression and low nuclear K116
acetylation correlate with increased interleukin (IL)-6 and NANOG
levels and with poor prognosis among colorectal cancer (CRC)
patients. a Representative immunoﬂuorescent images of CRC tissues
co-stained with antibodies directed against FRA1 (green), STAT3-
pY705 (red), NANOG (carmine), and DAPI (blue). Scale bars repre-
sent 50 μm. b Quantiﬁcation of immunohistochemically(IHC) deter-
mined FRA1 and K116Ac protein levels in nuclei and cytoplasm of
cells located within CRC tissue and in normal tissue regions from CRC
patients. c Representative IHC images of concurrent expression of
IL-6, FRA1, K116Ac, HDAC6, and NANOG proteins in consecutive
sections of CRC tissues from two different CRC patients. Scale bars
represent 50 μm. d Correlation analysis of HDAC6 and K116Ac
protein expression levels among CRC patients. e Correlation analysis
of relative mRNA expression levels of IL-6 and FOSL1 from
GSE24551-GPL5171 dataset [26]. f, g Overall patient survival nega-
tively correlates with high FRA1 protein level (e) and with its low
nuclear K116 acetylation (f). Log-rank (Mantel–Cox) test was here
employed for survival analysis
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impact on the IL-6-induced EMT changes, thus indicating
that c-Fos and its potential acetylation is independent of IL-
6/STAT3 pathway [3].
HDAC6 is a key histone deacetylase playing relevant
functional roles in different cellular compartments.
Although mainly localized in the cytoplasm, several lines of
evidence suggest that HDAC6 can also reside in the nucleus
and interact with nuclear proteins, including HDAC11;
sumoylated p300; transcriptional corepressors such as
ETO2 and L-CoR; and TFs such as NF-κB, Runx2, and P53
[34–36]. Here we show by western blot and IHC analysis
that HDAC6 localizes to both the nucleus and cytoplasm of
CRC cells and patient-derived tumor tissues. We identiﬁed
HDAC6 as the enzyme responsible for FRA1 K116 dea-
cetylation. FRA1 can physically interact with HDAC6 and
this interaction is strengthened by IL-6/STAT3 signaling.
Thus FRA1 regulation downstream of IL-6/STAT3 occurs
at two distinct levels: through the binding of phosphorylated
STAT3 to the FOSL1 promoter leading to its increased
transcription, and, at the posttranslational level, through
deacetylation of the lysine 116 residue, located within the
DBD and resulting in enhanced interaction with the pro-
moter of its target genes.
Among the genes known to regulate CSC properties, we
used JASPAR database (http://jaspar.genereg.net/) and
predicted that only NANOG, SOX2, and LGR5 encompass
AP-1-binding sequences within their promoters, thus sug-
gesting that they may represent downstream targets of the
IL-6/STAT3/FRA1 signaling axis. As shown here, only
NANOG does factually represent a direct FRA1 target gene.
The physical interaction between FRA1 and NANOG occurs
through a FRA1/AP-1-binding site (FBE) upstream of the
translational start site. FRA1 deacetylation at Lys-116
enhances this interaction and further activates NANOG
transcription.
It has been reported that CD24 regulates NANOG
expression through STAT3 phosphorylation and that
pSTAT3 (Y705) bound to the NANOG promoter drives
Fig. 7 Combined treatment of 5-Fluorouracil (5-FU) with the HDAC6
inhibitor Tubastatin A synergistically inhibits colorectal cancer stem-
like properties and malignant growth. a Western blot analysis of
nuclear and cytoplasmic extracts from sorted CD44−/CD133− and
CD44+/CD133+ DLD1 cells (as in Figure S1i) cultured with control or
interleukin-6 supplemented medium. K116 acetylation was detected
with the K116Ac antibody and normalized against the FRA1 protein.
b HDAC6 and FRA1 (total and K116Ac) western blot analysis of
CD44−/CD133− and CD44+/CD133+ DLD1 cells sorted by
ﬂuorescence-activated cell sorter. c Percentages of apoptotic (Annexin
V+) cells in sorted CD44−/CD133− and CD44+/CD133+ DLD1 cells
when exposed to 5-FU or Tubastatin A. d Percentages of apoptotic
cells in sorted CD44+/CD133+ DLD1 cells when exposed to dimethyl
sulfoxide (Ctrl), 5-FU, Tubastatin A, and 5-FU plus Tubastatin A. e
Effects of 5-FU, Tubastatin A, and of 5-FU with Tubastatin A admi-
nistered to BALB/C nude mice on day 8 when tumor had a diameter of
~5 mm from CD44+/CD133+ DLD1 cells. Histogram showing the
quantiﬁcation of the tumor mass
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tumor onset and self-renewal in the liver [12]. Moreover, it
was shown that NANOG expression in CRC is regulated by
extracellular insulin-like growth factor signaling via STAT3
phosphorylation [13]. Several studies have revealed the
importance of NANOG as a CSC maintainer in liver cancer
and CRC [10–12]. Our study showed that IL-6 treatment
enhanced FOSL1 and NANOG expression in a STAT3-
dependent fashion. Of interest, FOSL1 gene knockout sig-
niﬁcantly blocked IL-6-induced NANOG expression, while
NANOG overexpression in FOSL1 knockdown cells par-
tially rescued the negative effects of FOSL1 ablation on
chemo-resistance, self-renewal, and tumorigenesis. Notably,
NANOG knockdown signiﬁcantly inhibited IL-6 induced
in vitro ability of migration, invasion, chemo-resistance,
and self-renew and in vivo ability of tumorigenesis. Hence,
NANOG represents, presumably together with others [18], a
bona ﬁde downstream effector of FRA1, rather than
STAT3, in the regulation of CSC properties downstream of
IL-6. In human ESCs, transforming growth factor-β/Acti-
vin-responsive SMADs bind to the NANOG promoter and
play an essential role in sustaining self-renewal [37]. We
showed here that, in the context of inﬂammation and CRC,
the regulation of the NANOG stem-like pathway was
hijacked by the inﬂammatory IL-6/STAT3/FRA1 pathway.
These results were validated in a large (n= 123) cohort of
prospectively collected human colorectal carcinomas. We
found that, while FRA1 was mainly localized in the nucleus
of cancer cells, its acetylated form was mainly present in the
cytoplasm, i.e., indicative of low K116Ac levels in its
nuclear fraction. More importantly, high FRA1 protein
expression and its relatively low K116 acetylation levels in
the nucleus highly correlate with IL-6 secretion and with
poor prognosis and overall survival among CRC patients. In
summary, the results of western blots and IHC both showed
that IL-6 deacetylates FRA1-K116 in the CRC cells.
The elucidation of the cellular and molecular mechan-
isms underlying the enhancement of colon cancer stemness
downstream of the IL-6/STAT3/FRA1 signaling axis opens
novel opportunities to develop alternative and possibly
more effective therapeutic strategies. Small molecules
inhibiting lysine acetylation (HDAC inhibitors) have been
reported in the scientiﬁc literature, some of which with
Food andDrug Administrationapproval, for the treatment of
a broad spectrum of cancer-related pathologies. SAHA (also
known as Vorinostat) was approved to treat cutaneous T
cell lymphoma [20]. The antiepileptic drug valproic acid
also inhibits HDACs and is currently being employed in
several clinical trials for various indications [20]. Tubastatin
A is a neuroprotective and speciﬁc inhibitor of HDAC6
[38]. HDAC6 maintains glioma stem cells (GSCs) through
GLI1 signaling and its speciﬁc inhibition, when combined
with X-ray irradiation, suppresses the tumorigenic capacity
of GSCs in vivo [39].
5-FU represents one of the most common chemother-
apeutic drugs in the treatment of CRC. However, its cura-
tive effects as a single agent are far from optimal. As
observed in this study and supported by several previous
reports, the stem-like CD44+/CD133+ colon cancer cells
are chemo-resistant, a characteristic that is enhanced by IL-
6 stimulation and the subsequent FRA1 deacetylation. Here
we showed that the combination of 5-FU with the HDAC6
inhibitor Tubastatin A, designed to target both the more
committed CRC cells (by 5-FU) and the small but che-
moresistant CSC fraction (by Tubastatin A), dramatically
inhibited tumor growth in vivo with no signiﬁcant in vivo
toxicity. Hence, the combined treatment of a chemother-
apeutic agent with an HDAC6 inhibitor may offer an
improved and novel curative approach for CRC patients,
especially in those cases where the IL-6/STAT3/
FRA1 signaling axis is activated.
In conclusion, upon inﬂammation and IL-6 secretion
from the microenvironment, the STAT3 pathway becomes
activated and promotes CRC stemness and malignancy
through the transcriptional (promoter binding) and post-
translational (K116 deacetylation) upregulation of FOSL1/
FRA1. HDAC6 is responsible for the deacetylation of the
Lys-116 residue in FRA1. NANOG is a direct FRA1 target
gene likely to play a central role in conferring increased
stemness and malignancy to the cancer cell. Last, combi-
natorial treatment with a conventional cytotoxic agent (5-
FU) and an HDAC6 inhibitor (Tubastatin A) may offer
novel potential therapeutic options for CRC patients.
Materials and methods
Patient samples
A total of 123 human CRC samples were collected at the
Second Afﬁliated Hospital of Zhejiang University School of
Medicine after informed consent had been given by all
patients. The clinicopathological characteristics of the
clinical specimens are summarized in Supplementary Table
S2.
Statistical analysis
Data represent the mean ± SD of at least three independent
experiments. Animal studies were performed blinded. No
animals were excluded from study results. The animal
experimental groups were blinded to the experimentalists
during the experiment and data collection. BALB/C nude
mice (male, 5 weeks of age) were selected for each group in
a randomized fashion. The Log-rank (Mantel–Cox) test was
used for survival analysis. The two-tailed t test was used to
evaluate statistical differences in different groups. Pearson
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correlation and Spearman rank correlation tests were com-
puted to assess the relativity of two groups. All analyses
were performed using the GraphPad Prism6 software and
R x64 3.4.4 statistical software. #,*p < 0.05; ##,**p < 0.01;
###,***p < 0.001.
Study approval
All animal studies were reviewed and approved by the
Laboratory Animal Welfare Committee of Zhejiang Uni-
versity (approval number ZJU2015-282-01). The proce-
dures related to human subjects were approved by the
Medical Ethics Committee of Zhejiang University School of
Medicine (approval number 2015-013).
See Online Supplementary Material and Methods for
additional experimental procedures [40–49].
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